



**Press Release**  
**July 23 2020**

### **Thornton & Ross appoints Mick Cox to as lynchpin to growth**

Huddersfield-based pharmaceutical manufacturer Thornton & Ross, part of the STADA group, is underlining its growth ambitions with the appointment of Mick Cox as vice-president for consumer healthcare in the UK.

Mick's remit is to drive the sales growth of the company's current consumer portfolio – which includes household names such as Zoflora®, Covonia®, Oilatum® and Savlon® – as the business continues on its impressive growth trajectory.

Mick brings a wealth of experience in building high-profile, global brands, with a strong focus on profit and growth. He has a proven track record in creating innovation programs to generate sales growth across both developed and emerging markets.

He joins the business from Glaxosmithkline, where he was most recently vice-president for business integration, and before that was leading the Sensodyne brand to global sales over more than £1 billion. Mick began his career at Pfizer/Warner Lambert where he became a marketing specialist before moving to Kimberly Clark where he eventually became marketing director.

Mick's arrival follows the recent appointment of Prof Stephen Makin as head of research and development.

Executive vice-president Roger Scarlett-Smith welcomed Mick to the team, expressing delight that STADA was again investing in the UK side of the business.

"I am delighted to welcome Mick to the business, he will be a valuable addition to our senior team," said Roger. "He will play a pivotal role in promoting an innovation pipeline and driving brand penetration across the consumer healthcare division, through the energetic and creative leadership I know he will bring.

"He joins us at a time of continued expansion and will be a real asset in driving the business forward."

Mick added: "I am delighted to be joining such a dynamic and forward-thinking company, with its focus on caring for people's health. I am looking forward to working with the current teams to help further drive the business forward."

Thornton & Ross develops, manufactures and supplies a wide range of branded over-the-counter medicines, dermatological solutions and other healthcare and hygiene products including Natures Aid®, Hedrin® and Setlers®.

**-ENDS-**

Issued on behalf of Thornton & Ross by Faith PR. For further information please email [thorntonandross@faith-pr.co.uk](mailto:thorntonandross@faith-pr.co.uk) or call 01484 599886.



Image caption: Mick Cox, vice-president for consumer healthcare Thornton & Ross

#### **About Thornton & Ross Ltd**

Part of the STADA group, Thornton & Ross employs more than 500 people at its headquarters in Huddersfield, West Yorkshire. With a strong track record of supplying the NHS with emollients and bone health products, the company offers a wide and diverse portfolio of generic pharmaceuticals and over the counter healthcare solutions including Covonia<sup>®</sup>, Savlon<sup>®</sup> and Zoflora<sup>®</sup>. For more information go to [www.thorntonross.co.uk](http://www.thorntonross.co.uk)

#### **About STADA Arzneimittel AG**

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide. [www.stada.com/investor-relations](http://www.stada.com/investor-relations)